ATOPIC DERMATITIS
Clinical trials for ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Major trial tests new pill to tame severe eczema itch and rash
Disease control OngoingThis large, late-stage study tested whether a daily pill called upadacitinib, taken alongside a standard steroid skin cream, is effective and safe for controlling moderate to severe eczema (atopic dermatitis). It enrolled over 1500 teens and adults whose eczema was not well-contr…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Extended trial tests eczema Drug's staying power in kids
Disease control ENROLLING_BY_INVITATIONThis study aims to learn about the long-term safety and effectiveness of the drug lebrikizumab for children and teenagers with moderate-to-severe eczema. It is an extension study for about 310 participants who completed a previous trial, following them for up to 116 weeks. The ma…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Major trial tests if new eczema drug keeps skin clear long-term
Disease control OngoingThis study is checking the long-term safety and effectiveness of rocatinlimab, an investigational drug for moderate-to-severe eczema (atopic dermatitis). It involves over 2,600 adults and adolescents who previously took the drug in earlier studies. The main goal is to see if the …
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Pfizer tracks Real-World results for eczema drug in japan
Disease control OngoingThis study is observing how well and how safely the medicine CIBINQO works for treating atopic dermatitis (eczema) in people under real-world medical care in Japan. It involves over 1,100 participants who are starting or continuing treatment with the commercially available drug. …
Matched conditions: ATOPIC DERMATITIS
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New injection tested to tame severe teen eczema
Disease control OngoingThis study is testing an investigational drug called CM310 to see if it is safe and effective for teenagers with moderate-to-severe atopic dermatitis (eczema). About 180 adolescent participants will receive the drug via injection to see if it reduces their skin inflammation and i…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New ointment tested for itchy skin condition
Disease control ENROLLING_BY_INVITATIONThis is an early-stage study to check the safety and how the body processes a new ointment called CU-10101. It will involve 64 healthy adults and adults with mild to moderate atopic dermatitis (eczema). Researchers will apply the ointment to the skin to see how well it is tolerat…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Cutia Therapeutics(Wuxi)Co.,Ltd • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New pill aims to tame severe eczema itch and rash
Disease control OngoingThis study is testing whether an experimental daily pill called PF-08049820 is safe and effective for adults with moderate to severe eczema (atopic dermatitis). About 200 participants will take either the study pill or a placebo (a pill with no medicine) for 12 weeks. Doctors wil…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Light vs lotion: Head-to-Head eczema battle
Disease control OngoingThis study tests whether adding UVB light therapy to standard skin creams works better than using creams alone for adults with moderate-to-severe eczema. 316 participants were randomly assigned to receive either the light therapy plus creams or just creams for at least 3 months. …
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Can eczema patients take fewer shots and stay clear?
Disease control OngoingThis study is testing whether people with well-controlled eczema can safely take their medication (dupilumab) less often. It will compare a reduced dosing schedule to the standard schedule in 256 teens and adults over one year. The goal is to see if spacing out injections can mai…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug trial aims to tame severe childhood eczema
Disease control OngoingThis study is testing an investigational drug called lebrikizumab in children and teenagers with moderate-to-severe eczema. Participants are randomly assigned to receive either the drug or a placebo to see if it improves their skin condition and reduces itching. The main goals ar…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New pill aims to tame severe eczema Flare-Ups
Disease control OngoingThis study is testing whether an oral medication called jaktinib can help control moderate to severe atopic dermatitis, a form of eczema. It will compare the drug to a placebo in 443 adults to see if it significantly improves skin symptoms and is safe. The goal is to provide a ne…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New shot aims to tame severe eczema itch
Disease control OngoingThis study is testing whether an investigational drug called barzolvolimab can safely reduce severe itching and improve skin in adults with moderate to severe atopic dermatitis (eczema). About 131 participants will receive either the drug at one of two doses or a placebo via inje…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Tracking a common skin treatment: can methotrexate tame severe hand eczema?
Disease control OngoingThis study is observing 50 patients with moderate to severe hand eczema who are starting treatment with methotrexate, a medication that affects the immune system. Researchers will track how well the drug controls eczema symptoms, how long patients stay on it, and what side effect…
Matched conditions: ATOPIC DERMATITIS
Sponsor: Lone Skov • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New eczema duo enters human testing
Disease control OngoingThis early-stage study is testing a new combination of two drugs, APG777 and APG990, for adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to see if the combination is safe and how the body handles it, comparing it directly to an existing approved drug c…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New skincare line tested for eczema relief
Disease control OngoingThis study is testing whether a line of over-the-counter skincare products called Bodewell can help control eczema symptoms. Fifteen adults with moderate eczema will use the products for 12 weeks. Researchers will measure how much their skin improves and if their quality of life …
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for Kids' itchy skin: major trial tests eczema pill
Disease control OngoingThis study is testing whether adding an oral medication called upadacitinib to standard steroid creams is safe and works better for controlling moderate to severe eczema in young children in Japan. About 99 children aged 2 to 11 will take either the real pill or a placebo (sugar …
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Tracking a new eczema treatment for kids: does it work in everyday life?
Disease control OngoingThis study aims to understand how well the medication dupilumab works for children with severe eczema in real-world settings. It will follow 143 children in Spain, aged 6 months to 11 years, for two years to see how the treatment affects their skin, itch, and quality of life. The…
Matched conditions: ATOPIC DERMATITIS
Sponsor: Sanofi • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Two-Year watch: can this pill keep severe eczema at bay?
Disease control OngoingThis study is observing how well the already-approved oral medication upadacitinib (RINVOQ) works for controlling moderate-to-severe eczema over two years in real-world medical settings. It involves about 770 adolescents and adults in Germany who are already prescribed this medic…
Matched conditions: ATOPIC DERMATITIS
Sponsor: AbbVie • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New injection shows promise for controlling severe eczema
Disease control OngoingThis study is testing an experimental injection called APG777 for people with moderate-to-severe eczema (atopic dermatitis). Researchers want to see if different doses of APG777 can safely reduce skin inflammation and itching better than a placebo. The trial will last up to 2 yea…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New drug offers hope for severe eczema sufferers
Disease control OngoingThis study is testing whether a new injectable drug called lebrikizumab, used alone or with a standard steroid cream, can better control moderate-to-severe eczema. About 300 adults and adolescents whose eczema isn't well-controlled by current creams will participate for about 62 …
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New shot aims to tame severe eczema Flare-Ups
Disease control OngoingThis study is testing a new injectable drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 participants will receive either the drug or a placebo via injection every other week for 16 weeks, followed by the drug for another 32 weeks. Th…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New eczema shot for kids enters testing phase
Disease control OngoingThis trial is studying a drug called tralokinumab, given as an injection, to see how it behaves in the body and if it is safe and effective for children aged 6 to 12 with moderate-to-severe eczema. It will involve about 24 children and last for up to 194 weeks, including treatmen…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
Home injection trial aims to give eczema patients more control
Disease control OngoingThis study is testing whether people with moderate-to-severe eczema can successfully give themselves injections of an investigational medication called rocatinlimab at home. It involves 151 participants aged 12 and older who have not responded well to standard topical treatments.…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Baby skin cream trial aims to stop allergies before they start
Prevention OngoingThis study tests whether using special skin barrier creams and a steroid cream regularly (proactive care) in babies who already have eczema can prevent them from developing food allergies. It compares this approach to only treating eczema when it flares up (reactive care). The go…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Kari Nadeau, MD, PhD • Aim: Prevention
Last updated Apr 03, 2026 14:43 UTC
-
Bubble bath therapy tested for itchy, painful skin diseases
Symptom relief ENROLLING_BY_INVITATIONThis early study is testing a special bubble bath treatment called Thera-Clean for people with skin conditions like eczema, psoriasis, and epidermolysis bullosa. The treatment uses tiny bubbles to clean skin and wounds without chemicals, aiming to reduce itching, pain, odor, and …
Matched conditions: ATOPIC DERMATITIS
Phase: EARLY_PHASE1 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test if new skin drug changes how birth control and blood thinners work
Knowledge-focused OngoingThis early-stage study aims to understand how an experimental atopic dermatitis (eczema) drug called PF-08049820 affects how other medications move through the body. Researchers will test 16 healthy adult women to see if taking this drug changes how birth control pills, a sedativ…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 03, 2026 22:41 UTC
-
10-Year watch: does popular eczema cream pose cancer risk to kids?
Knowledge-focused OngoingThis is a long-term safety study, not a treatment trial. Researchers are following 8,000 children and teens with eczema for 10 years to see if using Elidel cream (pimecrolimus) increases their risk of developing cancers like lymphoma. The study is observing children who have alre…
Matched conditions: ATOPIC DERMATITIS
Sponsor: Bausch Health Americas, Inc. • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC
-
New antibody tested on healthy people for first time
Knowledge-focused OngoingThis is an early safety study testing a new antibody drug called SM17. It involves 30 healthy Chinese adults to check for side effects and see how the body processes the drug when given as an injection under the skin or into a vein. The main goal is to gather basic safety informa…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: SinoMab BioScience Ltd • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Massive 10,000-Person study tracks eczema drug results
Knowledge-focused ENROLLING_BY_INVITATIONThis study is creating a large national registry to track how well approved eczema (atopic dermatitis) treatments work and how safe they are in real-world settings. It will follow 10,000 adult patients under the care of a dermatologist who are starting a new medication. The goal …
Matched conditions: ATOPIC DERMATITIS
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Scientists track 2500 kids from birth to unlock allergy mystery
Knowledge-focused OngoingThis study aims to discover the earliest signs and biological causes of food allergies and eczema in children. Researchers will follow 2500 children from before birth until age 6, collecting samples and health information. The goal is to identify markers that predict which childr…
Matched conditions: ATOPIC DERMATITIS
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
A randomized, double-blind, placebo-controlled, multicenter, phase 2 study to evaluate the efficacy and safety of HY209 gel in patients with mild to moderate atopic Dermatitis(AD)
OngoingThis is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Shaperon
Last updated Mar 02, 2026 15:22 UTC